Skip to content

US · MLYS · BIOTECHNOLOGY

Mineralys Therapeutics, Inc. (MLYS) intrinsic value and stock valuation

$13.66as of 2026-11-21 · Mkt cap 2.37B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mineralys Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values MLYS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MLYS’s statements →

Mineralys Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Radnor, PA 19087 mineralystx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-154.65M
20202025
Free cash flow
-$-142.43M
20202025
Total equity
$646.7M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-170.6M-$-192.4M-$-84.66M-$-31.48M-$-18.73M
Net income-$-154.65M-$-177.81M-$-71.9M-$-29.8M-$-19.41M
EPSd-$-2.29M-$-3.66M-$-1.99M-$-5.76M-$-3.9M
Operating cash flow-$-142.42M-$-166.31M-$-81.17M-$-29.22M-$-14.56M
Capital expenditure-$-10K-$-100K$0.00$0.00$0.00
Free cash flow-$-142.43M-$-166.41M-$-81.17M-$-29.22M-$-14.56M
Total assets$661.8M$205.9M$251.6M$114.4M$11.1M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-172.92M-$-114.09M-$-49.3M-$-87.7M-$-10.61M
Total equity$646.7M$191.3M$241.2M-$-52.27M-$-22.93M
Cash and short-term investments$656.6M$198.2M$236.6M$110.1M$10.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$132M$168.6M$70.4M$26.3M$16.3M
Selling, general and administrative expenses$38.6M$23.8M$14.3M$5.23M$2.42M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$170.6M$192.4M$84.7M$31.5M$18.7M
Cost and expenses$170.6M$192.4M$84.7M$31.5M$18.7M
Interest income$16M$14.6M$12.8M$1.68M$0.00
Interest expense$0.00$0.00$0.00$1.68M$30K
Depreciation and amortization$60K$40K$0.00$0.00$0.00
Ebitda-$-154.59M-$-177.77M-$-71.9M-$-28.12M-$-19.38M
Operating income-$-170.6M-$-192.4M-$-84.66M-$-31.48M-$-18.73M
Total other income/expenses, net$16M$14.6M$12.8M$1.68M-$-680K
Income before tax-$-154.65M-$-177.81M-$-71.9M-$-29.8M-$-19.41M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-154.65M-$-177.81M-$-71.9M-$-29.8M-$-19.41M
Weighted average shares outstanding$67.7M$48.5M$36.2M$5.17M$4.98M
Weighted average diluted shares outstanding$67.7M$48.5M$36.2M$5.17M$4.98M
Balance sheet
20252024202320222021
Cash and short-term investments$656.6M$198.2M$236.6M$110.1M$10.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$661.4M$205.4M$249.1M$112.8M$11.1M
Property, plant and equipment, net$40K$50K$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$2.48M$0.00$0.00
Total non-current assets$420K$550K$2.53M$1.63M$0.00
Total assets$661.8M$205.9M$251.6M$114.4M$11.1M
Accounts payable$2.02M$480K$600K$1.91M$760K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$15.1M$14.7M$10.5M$8.07M$5.05M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$158.6M$29M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$15.1M$14.7M$10.5M$166.7M$34.1M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-457.17M-$-302.52M-$-124.71M-$-52.81M-$-23.01M
Accumulated other comprehensive income (loss)$0.00$0.00-$-251.64M$0.00$0.00
Total equity$646.7M$191.3M$241.2M-$-52.27M-$-22.93M
Total investments$483.7M$84.1M$189.8M$22.4M$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-172.92M-$-114.09M-$-49.3M-$-87.7M-$-10.61M
Cash flow statement
20252024202320222021
Net income-$-154.65M-$-177.81M-$-71.9M-$-29.8M-$-19.41M
Depreciation and amortization$60K$40K$0.00$0.00$0.00
Stock-based compensation$19.3M$11.3M$5.06M$460K$80K
Change in working capital$2.73M$9.52M-$-7.47M$770K$4.08M
Accounts receivable-$-170K$420K-$-350K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-142.42M-$-166.31M-$-81.17M-$-29.22M-$-14.56M
Investments in property, plant and equipment-$-10K-$-100K$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-389.75M$115M-$-160.47M-$-21.76M$0.00
Common stock issued$591M$116.1M$203M$0.00$23.8M
Common stock repurchased$0.00$0.00$0.00-$-1.63M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$591M$116.1M$203.3M$128M$23.8M
Net change in cash$58.8M$64.8M-$-38.4M$77M$9.25M
Cash at end of period$172.9M$114.1M$49.3M$87.7M$10.7M
Operating cash flow-$-142.42M-$-166.31M-$-81.17M-$-29.22M-$-14.56M
Capital expenditure-$-10K-$-100K$0.00$0.00$0.00
Free cash flow-$-142.43M-$-166.41M-$-81.17M-$-29.22M-$-14.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mineralys Therapeutics, Inc.

        Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

        CEO
        Jon Congleton
        Employees
        76
        Beta
        0.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Mineralys Therapeutics, Inc. (MLYS)?

        InvestorsCraft does not currently publish an intrinsic value for MLYS. How the IC value is calculated.

        Is MLYS undervalued?

        InvestorsCraft does not publish an undervaluation signal for MLYS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.